Evidence map›Paper›PMID 41111459›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Spatial Transcriptional Dynamics of CD74⁺ B Cells in Tertiary Lymphoid Structures Drive Immune Evolution in Penile Squamous Cell Carcinoma.

Ting Xue, Chuangzhong Deng, Jingya Liu, Ru Yan, Jing Li, Xiheng Hu, Xueying Li, Xiao Xiao, Jietian Jin, Hongzhen Tang and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Association of CCL21Cancer immunology, immunotherapy : CII · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ting XueState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Chuangzhong DengState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Jingya LiuBioMega Spatiotemporal Pathology Research Center, Zhuhai, 519000, China.
Ru YanDepartment of Oncology, Guizhou Provincial People's Hospital, Guizhou, 550008, China.
Jing LiDepartment of Urology, Cancer Hospital, Affiliated to Guangzhou Medical University, Guangzhou, 510030, China.
Xiheng HuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xueying LiDepartment of Oncology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China.
Xiao XiaoDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Jietian JinDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Hongzhen TangBioMega Spatiotemporal Pathology Research Center, Zhuhai, 519000, China.
Desi ChenDepartment of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518020, China.
Zihan ZuoClinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510060, China.
Yujie LiangShenzhen Kangning Hospital, Shenzhen, 518020, China.
Dongbin WangDongguan Key Laboratory of Public Health Laboratory Science, School of Public Health, Guangdong Medical University, Dongguan, 523808, China.
Bonan ChenDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Sir Y. K. Pao Cancer Center, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.ORCID https://orcid.org/0000-0002-2430-7934
Hui HanDepartment of Urology, Sun Yat sen University Cancer Center, Guangzhou, 510060, China.
Zaishang LiDepartment of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518020, China.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515012200Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515012321Basic and Applied Basic Research Foundation of Guangdong Province 2025A1515010257Guangdong Natural Science Foundation Enterprise-Research Collaboration Project 2021A1515220182National Natural Science Foundation of China 82403017Research Grants Council of Hong Kong Postdoctoral Fellowship Scheme UGC/GEN/562/3Shenzhen People's Hospital Clinical Scientist Cultivation Project SYWGSJCYJ202405Shenzhen Science and Technology Innovation Commission Outstanding Youth Basic Research Project RCYX20221008093032008
6 · The paper itself

Abstract

Penile squamous cell carcinoma (PSCC) is a malignancy characterized by a poor prognosis and lack of reliable biomarkers, presenting considerable therapeutic challenges. Tertiary lymphoid structures (TLSs) are critical modulators of antitumor immunity; however, the immunological dynamics, particularly the roles of B cells and their interactions with naive T cells in PSCC tissues, remain inadequately understood. This study integrates transcriptomic approaches, including spatial transcriptomics, single-cell sequencing (scRNA-seq), and bulk RNA sequencing (bulk RNA-seq), and immunohistochemistry to elucidate the immune architecture of and functional mechanisms within TLSs. The results reveal a positive correlation between TLS density and patient survival, with CD74⁺ B cells tending to be enriched during early TLS formation. These cells exhibit strong immune activation and a propensity to differentiate into plasma cells. By engaging with naive T cells through HLA-DRA via ligand-receptor interactions, CD74⁺ B cells activate transcription factors, including NFKB1, NFKB2, NFATC1, NFATC2, FOS, and RUNX1, in naive T cells, thereby enhancing the immune response. Consequently, CD74⁺ B cells represent a compelling biomarker for and therapeutic target of PSCC, offering profound insights into the immunological mechanisms that drive PSCC progression and response to immunotherapy.

Indexed as

Antigens, Differentiation, B-LymphocyteB-LymphocytesCarcinoma, Squamous CellPenile NeoplasmsTertiary Lymphoid StructuresHistocompatibility Antigens Class IIHumansMaleAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIinvariant chainCD74⁺ B cellsimmunotherapy targetpenile squamous cell carcinomaspatial transcriptomicstertiary lymphoid structures

Identifiers

PMID41111459
PMCPMC12667480

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.